News and Updates

NASA prepares for a landmark ISS mission featuring Dr. Anil Menon. Discover how this physician-astronaut is advancing the future of space medicine.

A new clinical trial confirms stem cell transplants for Parkinson's are safe and feasible, marking a major milestone in regenerative neurological medicine.

AstraZeneca and Ionis face a setback as their investigational heart drug misses primary endpoints in a Phase 3 trial. Discover what this means for patients.

AstraZeneca and Ionis face a setback as their ATTR-CM drug trial misses primary goals. See why analysts believe the market reaction may be an over-reaction.

New peer-reviewed data confirms the efficacy and safety of Yesafili in treating Diabetic Macular Edema, offering a robust biosimilar option for patients.

Regulators have ordered the withdrawal of an Amgen drug after evidence of data manipulation, highlighting critical lapses in clinical trial integrity.

AstraZeneca and Ionis face a setback after Wainua fails to meet primary endpoints in a recent heart disease trial. Learn the clinical and market implications.

Roche has discontinued two late-stage Huntington’s disease drug trials after data failed to show clinical efficacy in lowering toxic huntingtin protein.

AstraZeneca and Ionis end Phase 3 heart disease trial for eplontersen after failing to meet primary endpoints in patients with ATTR-CM.

A new clinical trial reveals that stem cell-derived dopamine cells are safe and effective for treating Parkinson’s disease symptoms. Learn more here.